Laparoscopically assisted Schauta operation: learning experience at the Gynecologic Oncology Unit, Buenos Aires University Hospital.

Abstract:

OBJECTIVES:The aim of this study was to show the learning experience of the employment of laparoscopic lymphadenectomy followed by a Schauta operation to treat patients with cervical carcinoma at a university hospital and to evaluate the feasibility, complications, hospital stay, delay in return to work, and overall survival of this procedure. METHODS:Between June 1, 1993, and December 30, 1997, 56 patients were selected. Surgical treatment began with a pelvic laparoscopic lymphadenectomy followed by a Schauta operation. Patients were staged according to FIGO criteria (Ia2, 10 cases; Ib1, 33 patients; Ib2, 8 cases; IIa, 3 cases; and IIb, 2 patients). Patients had a follow-up of 47 months. Overall survival was calculated with Kaplan-Meier tables. RESULTS:The procedure was not completed in 9 pts, in 5 cases among the first 20 pts that were entered on the trial due to technical problems and in 4 due to extracervical spread of disease (2 with gross laparoscopically unresectable lymph node metastases, 1 with parametrial infiltration, and 1 with rectovaginal septum involvement). In the 47 pts in which the procedure could be completed, the laparoscopic approach was done in 102 min and the vaginal part in 165 min. There were 4 complications: 1 ureteral injury, 1 abscess of the ischiorectal fossa, 1 hematoma of the Schuchardt incision, and 1 case of leg edema. The mean number of resected nodes was 17. Among the 47 cases in which the surgical procedure was completed, overall survival was 100% for Stage Ia, 88% for Ib1, and 85% for Ib2 after a mean follow-up of 4 years. Four pts have relapsed and died; 3 were stage Ib1 and the other was stage Ib2. They had pelvic recurrences. CONCLUSIONS:This surgery is secure and has an excellent outcome, so it can be considered a valid approach for the treatment of patients with cervical carcinoma, but in our hands, 20 cases were needed to obtain the minimum skill needed to perform it.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Sardi J,Vidaurreta J,Bermúdez A,di Paola G

doi

10.1006/gyno.1999.5588

subject

Has Abstract

pub_date

1999-12-01 00:00:00

pages

361-5

issue

3

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(99)95588-9

journal_volume

75

pub_type

杂志文章
  • A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors.

    abstract:OBJECTIVE:To evaluate the clinicopathological features of ovarian Sertoli-Leydig cell tumors (SLCTs) and to explore the reasonable therapy. METHODS:A total of 40 cases of SLCTs were retrospectively reviewed. RESULTS:The incidence of SLCTs was 0.41%, with a median age of 28 years. All tumors were confined to one ovary...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.07.114

    authors: Gui T,Cao D,Shen K,Yang J,Zhang Y,Yu Q,Wan X,Xiang Y,Xiao Y,Guo L

    更新日期:2012-11-01 00:00:00

  • Spontaneous arterial thrombosis with an advanced ovarian malignancy.

    abstract::Arterial thromboembolic disease almost always occurs in the setting of significant cardiovascular disease. Fewer than 10% of patients have no known etiology and only rarely is malignancy implicated. A review of the literature revealed only one prior report associated with a gynecologic malignancy, and this occurred in...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1996.4533

    authors: Minjarez DA,Delorit MA,Davidson SA

    更新日期:1997-01-01 00:00:00

  • Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.

    abstract:OBJECTIVES:Although the reported incidence of carboplatin hypersensitivity is low, its occurrence is important to characterize because of potential fatal complications. The purpose of this study was to determine the current incidence of carboplatin hypersensitivity in the ovarian cancer patients compared to other oncol...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.04.002

    authors: Navo M,Kunthur A,Badell ML,Coffer LW 2nd,Markman M,Brown J,Smith JA

    更新日期:2006-11-01 00:00:00

  • Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy?

    abstract:OBJECTIVE:Benefits of laparoscopy over laparotomy in patients with endometrial cancer (EC) are well known. As many patients with EC carry co-morbid conditions, surgery is exposing them to increased risk of complications. A review of the patients with EC recruited so far in a clinical trial comparing laparoscopy to lapa...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/j.ygyno.2004.12.048

    authors: Tozzi R,Malur S,Koehler C,Schneider A

    更新日期:2005-04-01 00:00:00

  • Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study.

    abstract:OBJECTIVES:Both paclitaxel and cisplatin have moderate activity in patients with metastatic or recurrent carcinoma of the endometrium, and the combination of these two agents has shown activity in a variety of solid tumors. We administered this combination to patients with metastatic or recurrent carcinoma of the endom...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1006/gyno.2000.5827

    authors: Dimopoulos MA,Papadimitriou CA,Georgoulias V,Moulopoulos LA,Aravantinos G,Gika D,Karpathios S,Stamatelopoulos S

    更新日期:2000-07-01 00:00:00

  • The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma.

    abstract::Benign cystic mesothelioma is a tumor characteristically found in women during the reproductive years. These tumors are infrequently found after castration or menopause, suggesting some degree of hormonal sensitivity. Such aspects of the tumor suggest a potential role for antiestrogens as medical management and an alt...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5031

    authors: Letterie GS,Yon JL

    更新日期:1998-07-01 00:00:00

  • 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

    abstract:OBJECTIVES:53BP1, a critical mediator of the DNA damage response, functions by regulating the balance between homologous recombination (HR) and the more error-prone non-homologous endjoining (NHEJ). Deletion of 53BP1 in brca1 (but not brca2) null cells partially restores HR and reverses sensitivity to poly-ADP-ribose p...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.12.007

    authors: Pennington KP,Wickramanayake A,Norquist BM,Pennil CC,Garcia RL,Agnew KJ,Taniguchi T,Welcsh P,Swisher EM

    更新日期:2013-03-01 00:00:00

  • Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case.

    abstract::Hypersensitivity reactions to intravenous administration of carboplatin (CP) have been previously reported. However, hypersensitivity reaction to intraperitoneal administration of CP has not yet been reported. A 66-year-old woman diagnosed with ovarian carcinoma underwent six courses of intraperitoneal administration ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1998.5273

    authors: Shukunami K,Kurokawa T,Kawakami Y,Kubo M,Kotsuji F

    更新日期:1999-03-01 00:00:00

  • Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma.

    abstract::During the period 1977 to 1985, 12 patients with FIGO stage II and III epithelial ovarian carcinoma failed to achieve a pathologic complete response with chemotherapy and underwent salvage whole-abdominal irradiation (WAXRT). Six of these patients had gross residual disease present at the time of irradiation, and thre...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90135-8

    authors: Linstadt DE,Stern JL,Quivey JM,Leibel SA,Lacey CG

    更新日期:1990-03-01 00:00:00

  • Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.

    abstract::The role of adjuvant chemotherapy in surgically staged stage I clear cell ovarian cancer (OCCC) is unclear. Here, we performed a systematic review and meta-analysis in order to evaluate the role of chemotherapy vs. observation in stage I OCCC. This systematic review was registered in the International Prospective Regi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ygyno.2019.12.045

    authors: Bogani G,Ditto A,Lopez S,Bertolina F,Murgia F,Pinelli C,Chiappa V,Raspagliesi F

    更新日期:2020-04-01 00:00:00

  • Clinical evaluation of radioimmunoimaging with 131I-C0C183B2 monoclonal antibody against ovarian carcinoma by intraperitoneal injection.

    abstract::Forty-eight cases subjected to radioimmunoimaging (RII) by intraperitoneal injection with 131I-C0C183B2 monoclonal antibody (MAb) prepared in our laboratory were studied. Thirteen of 14 cases of proved primary ovarian carcinoma were positive. In 11 follow-up cases of ovarian carcinoma after initial surgery and chemoth...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(92)90109-v

    authors: Qian H,Feng J,Cui H,Gao B,Qi G,Fu T,Wei P,Fu Z

    更新日期:1992-11-01 00:00:00

  • Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.

    abstract:OBJECTIVE:To evaluate the utility of amiodarone and its derivative dronedarone as novel drug repositioning candidates in EOC and to determine the potential pathways targeted by these drugs. METHODS:Drug-predict bioinformatics platform was used to assess the utility of amiodarone as a novel drug-repurposing candidate i...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.09.019

    authors: Belur Nagaraj A,Joseph P,Kovalenko O,Wang Q,Xu R,DiFeo A

    更新日期:2018-12-01 00:00:00

  • Endometrial response to endogenous hormones after pelvic irradiation for genital malignancies.

    abstract::Two cases are presented which demonstrate histologically an endometrial response to endogenous hormones after pelvic teletherapy and brachytherapy in patients who have undergone lateral ovarian transposition. Reasons for such a response are briefly discussed. ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90118-5

    authors: Larson JE,Whitney CW,Zaino R,Kaminski P,Podczaski E,Mortel R

    更新日期:1990-01-01 00:00:00

  • Racial disparities in surgical care for uterine cancer.

    abstract:OBJECTIVE:To evaluate the association of race and surgical approach for women who underwent surgical treatment for uterine cancer. METHODS:The design was a retrospective cohort study of discharge data from nonfederal acute care hospitals in Maryland from 2000 to 2009. Women aged 18 and older who underwent hysterectomy...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.02.004

    authors: Fleury AC,Ibeanu OA,Bristow RE

    更新日期:2011-06-01 00:00:00

  • Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study).

    abstract::By serendipity we have had the opportunity to evaluate cis-platin-based chemotherapy in ovarian tumors of low malignant potential (LMP). Optimal (less than 1 cm residual disease) FIGO stage III ovarian carcinomas were randomly assigned to treatment with cisplatin plus cyclophosphamide with or without doxorubicin on a ...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(91)90314-u

    authors: Sutton GP,Bundy BN,Omura GA,Yordan EL,Beecham JB,Bonfiglio T

    更新日期:1991-06-01 00:00:00

  • The Wertheim hysterectomy: Development, modifications, and impact in the present day.

    abstract::Ernst Wertheim was a pioneer in the history of the surgical treatment of cervical cancer. His English-language manuscript "The extended abdominal operation for carcinoma uteri (based on 500 operative cases)," which was published in 1912, detailed his standardization of the radical hysterectomy and formed the basis of ...

    journal_title:Gynecologic oncology

    pub_type: 历史文章,杂志文章

    doi:10.1016/j.ygyno.2017.01.011

    authors: Swailes AL,Gockley A,Phaëton R,Kesterson JP

    更新日期:2017-04-01 00:00:00

  • A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage IB cervical cancer.

    abstract:OBJECTIVES:Limited knowledge exists about the value of tumor size in surgically treated cervical cancer (CX) using a tumor size of 2 cm as cut-off value. METHODS:A total of 366 cases of CX FIGO stage IB who received upfront surgery were evaluated regarding tumor size, the prediction of pelvic lymph node involvement, a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.04.011

    authors: Horn LC,Bilek K,Fischer U,Einenkel J,Hentschel B

    更新日期:2014-07-01 00:00:00

  • Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.

    abstract:OBJECTIVES:We aimed to define the site-specific patterns of treatment failure in stage IV ovarian cancer. METHODS:Data from all consecutive Mayo Clinic patients with stage IV epithelial ovarian cancer, from 1994 through 2003, were collected and analyzed. Statistical analyses included the chi(2) test and Kaplan-Meier c...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.09.010

    authors: Aletti GD,Podratz KC,Cliby WA,Gostout BS

    更新日期:2009-01-01 00:00:00

  • Importance of serum sialic acid and lactate dehydrogenase in diagnosis and treatment monitoring of cervical cancer patients.

    abstract::In an attempt to establish a blood-based biochemical index for diagnosis of cervical cancer and treatment monitoring of patients suffering from the disease, serum levels of total sialic acid (TSA), lipid-bound sialic acid (LSA), and lactate dehydrogenase were estimated by highly specific spectrophotometric methods. Se...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1993.1214

    authors: Patel PS,Rawal GN,Balar DB

    更新日期:1993-09-01 00:00:00

  • The accuracy of frozen section by tumor weight for ovarian epithelial neoplasms.

    abstract::This study evaluated the effect ovarian weight has on the accuracy of frozen sections in serous and mucinous ovarian tumors. The study group included 294 patients who had an initial frozen section (189 serous and 105 mucinous tumors) at surgery. The pathology reports were separated into subgroups (benign, borderline, ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1997.4836

    authors: Puls L,Heidtman E,Hunter JE,Crane M,Stafford J

    更新日期:1997-10-01 00:00:00

  • A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.

    abstract:OBJECTIVE:The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers. METHODS:Women with advanced or recurrent MMMT were treated every 28 days with cisplatin (75 mg/m(2...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0090-8258(03)00332-9

    authors: Ramondetta LM,Burke TW,Jhingran A,Schmandt R,Bevers MW,Wolf JK,Levenback CF,Broaddus R

    更新日期:2003-09-01 00:00:00

  • Methotrexate-resistant mechanisms in human choriocarcinoma cells.

    abstract::Choriocarcinoma cells grown in the presence of methotrexate (MTX) developed resistance in two ways. HCCM-derived sublines (relatively high MTX resistance) produced enhanced levels of dihydrofolate reductase (DHFR) and had impaired transport of MTX. Altered transport was the primary determinant of response in CC1-deriv...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90095-4

    authors: Sakai K,Wake N,Fujino T,Yasuda T,Kato H,Fujimoto S,Fujinaga K

    更新日期:1989-07-01 00:00:00

  • Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.

    abstract:OBJECTIVE:To investigate the role of Bcl-X(L) on the growth and survival of human ovarian carcinoma cells. METHODS:In this study, we enforced down-regulation of Bcl-X(L) by RNA interference in ovarian carcinoma cell lines CaOV3, SKOV3ip1 and OVCAR3 cell lines expressing various levels of Bcl-X(L). We also established ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.08.028

    authors: Dodier P,Piché A

    更新日期:2006-02-01 00:00:00

  • Malignant pericardial effusion in ovarian carcinoma cured by systemic chemotherapy.

    abstract::A case of malignant pericardial effusion in a 67-year-old patient with serous ovarian cystadenocarcinoma is presented. Pericardial effusion was treated successfully with cyclophosphamide, doxorubicin, and cisplatin. The primary tumor had previously been assumed to be sensitive to this combination by using an in vivo p...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(88)90036-4

    authors: Mäenpää J,Taina E,Erkkola R

    更新日期:1988-06-01 00:00:00

  • Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.

    abstract:PURPOSE:The MDS1 and EVI1 complex locus (MECOM) at 3q26 gives rise to several alternatively spliced transcripts implicated in leukemic oncogenesis. Overexpression of EVI1 in ovarian cancer has led to a proposed oncogenic role. Our objective was to evaluate the therapeutic potential of EVI1 and EVI1s (also known as Delt...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.04.007

    authors: Jazaeri AA,Ferriss JS,Bryant JL,Dalton MS,Dutta A

    更新日期:2010-08-01 00:00:00

  • A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

    abstract:OBJECTIVE:To assess the safety and efficacy of pegylated liposomal doxorubicin (PLD), carboplatin, plus bevacizumab in patients with ovarian, fallopian tube, or primary peritoneal cancer. METHODS:Patients with platinum-sensitive, recurrent disease received PLD 30 mg/m(2) and carboplatin area under the curve (AUC) 5 on...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2012.05.028

    authors: del Carmen MG,Micha J,Small L,Street DG,Londhe A,McGowan T

    更新日期:2012-09-01 00:00:00

  • Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

    abstract:OBJECTIVE:To evaluate, from a societal perspective, the cost-effectiveness of adding bevacizumab to first-line therapy based on outcomes from the GOG-218 and ICON-7 trials. METHODS:A three-state Markov model was used. The time horizon was until the death of 99% of the initial cohort of 1000 individuals. Costs and qual...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.01.021

    authors: Mehta DA,Hay JW

    更新日期:2014-03-01 00:00:00

  • Analysis of vitamin D receptor expression and clinical correlations in patients with ovarian cancer.

    abstract:OBJECTIVE:Although the antiproliferative and differentiating properties of vitamin D have been demonstrated, its effects on cancer cells are variable. Little is known about vitamin D receptor (VDR) levels in patients with ovarian cancer. In this population we sought to determine correlations between VDR expression, cli...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.06.008

    authors: Silvagno F,Poma CB,Realmuto C,Ravarino N,Ramella A,Santoro N,D'Amelio P,Fuso L,Pescarmona G,Zola P

    更新日期:2010-10-01 00:00:00

  • Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

    abstract:BACKGROUND:Several cytokines have been associated with immune regulation and prognosis in ovarian cancer. CD4+CD25+ Tregs and CD3+CD56+ NK-like T cells are involved in the immune response against the tumor. We have investigated the association of cytokines in the ascites from patients with ovarian cancer with these pop...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.10.018

    authors: Bamias A,Koutsoukou V,Terpos E,Tsiatas ML,Liakos C,Tsitsilonis O,Rodolakis A,Voulgaris Z,Vlahos G,Papageorgiou T,Papatheodoridis G,Archimandritis A,Antsaklis A,Dimopoulos MA

    更新日期:2008-02-01 00:00:00

  • Changes in health-related quality of life in older women after diagnosis with gynecologic cancer.

    abstract:PURPOSE:The impact of gynecologic cancer on health-related quality of life (HRQOL) is not fully understood. To our knowledge, this is the first longitudinal study to measure HRQOL changes from before to after gynecologic cancer diagnosis in older women. METHODS:Data were obtained from the Surveillance, Epidemiology, a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.11.033

    authors: Klapheke AK,Keegan THM,Ruskin R,Cress RD

    更新日期:2020-02-01 00:00:00